About Scribe Therapeutics. Scribe Therapeutics is revolutionizing the development of optimized in vivo CRISPR-based genetic ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Mid-cap stocks represent companies valued at between $2 billion and $10 billion. If they give investors a reason to be ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

Analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued on Monday, January 6th. Brookline Capital Management ...

Scribe Therapeutics is slimming down its workforce by 20% as it readies its cardiometabolic pipeline for the clinic, a ...

B iotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to develop one or or even a handful of world-changing drug ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

Scribe Therapeutics, a biotech co-founded by CRISPR pioneer Jennifer Doudna, is reducing its workforce by about 20%.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...